Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Adaptive Biotechnologies Corp Director's Dealing 2020

Aug 13, 2020

31660_dirs_2020-08-12_6ec68439-0624-400c-b69a-0ba7805d5137.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-08-10

Reporting Person: ROBINS CHAD M (Director, CEO and Chairman)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-08-10 Common Stock M 16680 $0.33 Acquired 1794860 Direct
2020-08-10 Common Stock S 16680 $37.63 Disposed 1778180 Direct
2020-08-11 Common Stock M 16680 $0.33 Acquired 1794860 Direct
2020-08-11 Common Stock S 4937 $36.51 Disposed 1789923 Direct
2020-08-11 Common Stock S 9743 $37.40 Disposed 1780180 Direct
2020-08-11 Common Stock S 2000 $37.96 Disposed 1778180 Direct
2020-08-12 Common Stock M 16680 $0.33 Acquired 1794860 Direct
2020-08-12 Common Stock S 901 $36.80 Disposed 1793959 Direct
2020-08-12 Common Stock S 6774 $37.50 Disposed 1787185 Direct
2020-08-12 Common Stock S 9005 $38.43 Acquired 1778180 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-08-10 Stock Option (Right to Buy) $0.33 M 16680 Disposed 2021-12-20 Common Stock (16680) Direct
2020-08-11 Stock Option (Right to Buy) $0.33 M 16680 Disposed 2021-12-20 Common Stock (16680) Direct
2020-08-12 Stock Option (Right to Buy) $0.33 M 16680 Disposed 2021-12-20 Common Stock (16680) Direct

Footnotes

F1: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.23 to 38.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.89 to 36.87, inclusive.

F4: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.89 to 37.87, inclusive.

F5: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.89 to 38.03, inclusive.

F6: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.68 to 36.94, inclusive.

F7: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.09 to 38.07, inclusive.

F8: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.09 to 38.90, inclusive.

F9: The options are fully vested and exercisable.